成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. NF-κB MAPK/ERK Pathway JAK/STAT Signaling Stem Cell/Wnt
  3. IKK JNK STAT p38 MAPK ERK
  4. Peramivir

Peramivir  (Synonyms: 帕拉米韋; RWJ-270201; BCX-1812)

目錄號: HY-17015A 純度: 99.32%
COA 產(chǎn)品使用指南 技術(shù)支持

Peramivir 是一種的新型環(huán)戊烷神經(jīng)氨酸酶 (novel cyclopentane neuraminidase) 流感病毒抑制劑。Peramivir 具有抗病毒活性和抗細(xì)胞因子作用，可用于新型冠狀病毒肺炎的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Peramivir Chemical Structure

Peramivir Chemical Structure

CAS No. : 330600-85-6

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
1 mg ￥285
In-stock
5 mg ￥640
In-stock
10 mg ￥1040
In-stock
25 mg ￥2000
In-stock
50 mg ￥3200
In-stock
100 mg ￥4480
In-stock
500 mg 現(xiàn)貨 詢價
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Peramivir:

查看 IKK 亞型特異性產(chǎn)品:

查看 JNK 亞型特異性產(chǎn)品:

查看 STAT 亞型特異性產(chǎn)品:

查看 p38 MAPK 亞型特異性產(chǎn)品:

查看 ERK 亞型特異性產(chǎn)品:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19[1][2][3].

IC50 & Target

IKK-α

 

STAT3

 

ERK1

 

ERK2

 

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
HEK293 IC50
0.07 nM
Compound: 5
Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad
Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad
[PMID: 27167096]
HEK293 IC50
0.3 nM
Compound: 5
Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub
Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub
[PMID: 27167096]
HEK293 IC50
0.7 nM
Compound: 5
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure
[PMID: 27167096]
HEK293 IC50
0.8 nM
Compound: 5
Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure
Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure
[PMID: 27167096]
HEK293 IC50
146 nM
Compound: 5
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas
[PMID: 27167096]
HEK293 IC50
225 nM
Compound: 5
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas
Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas
[PMID: 27167096]
HEK293 IC50
3.3 nM
Compound: 5
Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by
Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by
[PMID: 27167096]
HEK293 IC50
3.6 nM
Compound: 5
Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft
Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft
[PMID: 27167096]
MDCK CC50
> 1 x 105 nM
Compound: 4; PE
Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay
Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay
[PMID: 29324342]
MDCK CC50
> 1 x 105 nM
Compound: 5
Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay
Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay
[PMID: 27167096]
MDCK CC50
> 100 μM
Compound: Peramivir
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 34700269]
MDCK CC50
> 200 μM
Compound: Peramivir
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 31954881]
MDCK IC50
0.2 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
[PMID: 19651908]
MDCK IC50
0.2 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo
[PMID: 19651908]
MDCK IC50
0.28 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay
Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay
[PMID: 20194700]
MDCK IC50
0.3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
0.3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
0.3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
[PMID: 19651908]
MDCK IC50
0.3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
0.3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12
[PMID: 19651908]
MDCK IC50
0.43 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay
[PMID: 20194700]
MDCK IC50
0.5 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay
Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay
[PMID: 20194700]
MDCK IC50
0.51 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay
[PMID: 20194700]
MDCK IC50
0.9 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay
[PMID: 20194700]
MDCK IC50
1 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
[PMID: 19651908]
MDCK IC50
1.47 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay
[PMID: 20194700]
MDCK EC50
1.5 nM
Compound: 5
Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay
Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay
[PMID: 27167096]
MDCK IC50
1.72 nM
Compound: Peramivir
Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
[PMID: 20713668]
MDCK IC50
142.4 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
213 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus
[PMID: 19651908]
MDCK IC50
214.07 nM
Compound: peramivir
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay
Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay
[PMID: 20194700]
MDCK IC50
27 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
[PMID: 19651908]
MDCK IC50
3 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam
[PMID: 19651908]
MDCK IC50
3 nM
Compound: Peramivir
Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
[PMID: 20713668]
MDCK IC50
3.51 nM
Compound: Peramivir
Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
[PMID: 20713668]
MDCK IC50
33.56 nM
Compound: peramivir
Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay
Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay
[PMID: 20194700]
MDCK CC50
373 μM
Compound: 3
Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay
Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay
[PMID: 29141777]
MDCK IC50
43.6 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
562.1 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
82.8 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal
[PMID: 19651908]
MDCK IC50
891.4 nM
Compound: Peramivir
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose
[PMID: 19651908]
MDCK IC50
9.43 nM
Compound: Peramivir
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay
[PMID: 20713668]
MDCK IC50
95.5 nM
Compound: Peramivir
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus
Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus
[PMID: 19651908]
體外研究
(In Vitro)

Peramivir (0.3125-40 μM, 4 h) 對巨噬細(xì)胞無毒性[1]。
Peramivir (2-10 μM, 6-12 h) 抑制 LPS 誘導(dǎo)的 hPBMCs 細(xì)胞因子釋放[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: RAW 264.7
Concentration: 0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 4 h
Result: Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.
體內(nèi)研究
(In Vivo)

Peramivir (20-60 mg/kg，腹腔注射，單次劑量) 可抑制 LPS 誘導(dǎo)的細(xì)胞因子風(fēng)暴，減輕急性肺損傷，延長細(xì)胞因子風(fēng)暴綜合征模型小鼠的生存時間[1]。
Peramivir (75 mg/kg，肌肉注射，每天 1 次，連續(xù) 7 天) 在 B 型流感病毒感染的免疫抑制小鼠模型中拯救了 BR/08 致死性攻擊的 BALB scid 小鼠[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Cytokine storm syndrome model mice [1]
Dosage: 20 mg/kg, 60 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12.
Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion.
Showed significant protective effects to the lung tissues.
Animal Model: Immunocompromised murine models of infuenza B virus infection[2]
Dosage: 75 mg/kg
Administration: Intramuscular injection (i.m.)
Result: Conferred complete protection against lethality, whether it was administered in one (1×), two (2×), or four (4×) doses, with maximum mean weight loss of 10% to 14%.
Resulted in a trend of decreasing virus replication in the nasal cavities and lungs.
Reduced the virus titers and replication.
Clinical Trial
分子量

328.41

Formula

C15H28N4O4
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

帕拉米韋
運輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細(xì)胞實驗： 

DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物溶解方案計算器
請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實驗過程有損耗，建議您多配一只動物的量
計算結(jié)果
工作液所需濃度 : mg/mL
純度 & 產(chǎn)品資料

純度: 99.32%

參考文獻(xiàn)
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Peramivir
目錄號：
HY-17015A
需求量：